Separately, Zacks Investment Research lowered shares of CHF Solutions from a hold rating to a sell rating in a research report on Tuesday, November 12th.
Shares of CHFS stock opened at $0.93 on Tuesday. The stock has a market cap of $3.09 million, a P/E ratio of -0.02 and a beta of 2.25. CHF Solutions has a one year low of $0.60 and a one year high of $13.90. The stock has a fifty day moving average price of $0.96 and a 200 day moving average price of $2.24. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.06 and a quick ratio of 1.51.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. A.R.T. Advisors LLC bought a new stake in shares of CHF Solutions in the 2nd quarter valued at approximately $34,000. Anson Funds Management LP bought a new position in shares of CHF Solutions during the 2nd quarter worth approximately $278,000. Finally, Virtu Financial LLC bought a new position in shares of CHF Solutions during the 3rd quarter worth approximately $48,000. 8.49% of the stock is currently owned by institutional investors.
CHF Solutions Company Profile
CHF Solutions, Inc, a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company's commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
See Also: Market Capitalization
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.